| Pronunciation |
 (HEE
min) |
 |
| U.S. Brand Names |
| Panhematin® |
|
| Generic Available |
|
No |
|
| Pharmacological Index |
|
Blood Modifiers |
|
| Use |
|
Treatment of recurrent attacks of acute intermittent porphyria (AIP) only after an appropriate period of alternate therapy has been tried |
|
| Contraindications |
|
Porphyria cutanea tarda; hypersensitivity to hemin |
|
| Adverse Reactions |
|
1% to 10%: Hematologic: Leukocytosis Local: Phlebitis |
|
| Drug Interactions |
|
Estrogens, barbiturates, corticosteroids, anticoagulants |
|
| Usual Dosage |
|
I.V.: 1-4 mg/kg/day administered over 10-15 minutes for 3-14 days; may be repeated no earlier than every 12 hours; not to exceed 6 mg/kg in any 24-hour period |
|
| Mental Health: Effects on Mental Status |
|
None reported |
|
| Mental Health: Effects on Psychiatric Treatment |
|
Avoid concurrent use with barbiturates |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Dosage Forms |
|
Powder for injection, preservative free: 313 mg/vial [hematin 7 mg/mL] (43 mL) |
|
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
